Loading...
XSHE
300439
Market cap563mUSD
Dec 05, Last price  
10.36CNY
1D
0.39%
1Q
-3.18%
Jan 2017
-65.68%
IPO
-28.65%
Name

MedicalSystem Biotechnology Co Ltd

Chart & Performance

D1W1MN
XSHE:300439 chart
P/E
15.43
P/S
2.29
EPS
0.67
Div Yield, %
1.29%
Shrs. gr., 5y
2.31%
Rev. gr., 5y
-11.07%
Revenues
1.74b
-7.61%
192,520,105327,742,449432,061,495597,849,201683,141,1601,059,147,0702,584,187,5653,135,122,9193,133,447,6972,302,032,4212,251,532,2062,489,086,2161,885,869,2161,742,424,499
Net income
258m
+0.56%
53,328,06891,734,676103,529,869137,684,356161,267,521174,494,721229,700,185241,172,0820299,480,578179,488,034198,527,038256,551,420257,997,230
CFO
398m
-37.21%
49,824,50046,778,385100,063,948116,510,814177,548,0862,453,7050418,803,231601,170,720912,074,949515,482,463564,665,289633,532,150397,812,147
Dividend
Jun 07, 20240.134 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Medicalsystem Biotechnology Co., Ltd. provides clinical diagnostics reagents and instruments in China. The company offers PCR kit, antibody test kit, antigen test kit, and nucleic acid reagent for COVID-19; automated biochemistry analyzers and bio reagents; hematology analyzers; urine analyzers; glycated hemoglobin analyzer; POCT; and chemiluminescene immunoassay analyzers. It also provides healthcare services. The company was formerly known as Ningbo Medicalsystem Biotechnology Co., Ltd. and changed its name to Medicalsystem Biotechnology Co., Ltd. in January 2017. Medicalsystem Biotechnology Co., Ltd. was founded in 2003 and is based in Ningbo, China.
IPO date
Apr 22, 2015
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT